Trial Profile
A Randomized, Double-Blind, Losartan-Controlled, Parallel Group Comparison Dose Titration Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan 60mg-120mg in Patients With Mild to Moderate Essential Hypertension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Fimasartan (Primary) ; Losartan
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Boryung Pharmaceutical
- 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
- 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
- 28 Feb 2012 Results published in Clinical Therapeutics.